Biocryst outlines $415M-$425M 2026 operating expense guidance while keeping ORLADEYO at $625M-$645M
Open the sourceReported by Seeking Alpha, seekingalpha.com, 4 November 2026
50Impact 50 of 100, routine
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at seekingalpha.com.
Named in this story
BioCryst Pharmaceuticals, ORLADEYO